

Modules
Menu
In Vitro Pharmacology
Oncology
- India’s largest tumor bank repository with human cancer cell lines representing 15 – 20 different cancer types
- Characterized cell lines from authenticated sources
- Inclusive of untransformed cell lines to enable early safety assessment
- Drug resistant cell lines & primary cultures from human biopsies
- Complete repertoire of viability & cytotoxicity assessment screens
- Customized Molecular target based screens
- Combination index studies for assessment of synergy
In Vitro Services
Model | Evaluation of drug interactions in combination cancer chemotherapy by combination index method |
Test system |
|
Methods |
|
End points |
Categorization of drug combinations as synergistic/additive/antagonistic for each combination tested. |
Model | DETERMINATION OF SYNERGISTICALLY EFFICACIOUS COMBINATION(S) OF CISPLATIN AND DOXORUBICIN IN HepG-2 CELL LINE IN VITRO BY COMBINATION INDEX METHOD |
Test system |
|
Methods |
|
End points |
Cells were treated at fixed IC50 of one drug (Cisplatin/Doxorubicin) in combination with variable concentrations of the other (Cisplatin/Doxorubicin). MTT assay CI value was calculated to assess the synergistic effect of test items Synergism, additive or antagonism was based on the following criteria:
|
Model | in vivo: model to quantitate intracellular uptake and localization of drugs (e.g. Nanoparticle/liposomal formulations) |
Test system |
|
Methods |
|
End points |
|
Model | Assessment of anti-cancer activity of the compounds using tube formation assay |
Test system |
|
Methods |
|
End points |
|
Cell Migration assay
Model | Assessment of anti-cancer activity of the compounds using cell migration assay |
Test system | HUVEC Cells |
Method |
|
End points |
|
In vitro Angiogenesis model
Model | Assessment of anti-cancer activity of the compounds using tube formation assay |
Test system | HUVEC Cells |
Method |
|
End points | Quantitative analysis of –
|
In vitro angiogenesis VEGF
Model | Assessment of VEGF, bFGF & Endostatin |
Test system | HUVEC, MDA-MB-231, MCF-7, HCT-116 etc |
Method |
|
End points |
|
Model | Complete repertoire of Screens for assessment of Programmed cell death to enable selection of Proapoptotic & antiapoptotic molecules |
Test system |
|
Apoptotic Pathways |
|
End points |
|
Model | Assessment of anti-leukemic activity of the compounds in SCID mice |
Test system | SCID mice |
Models |
|
End points |
|
Core team of Biochemists, Cell biologists & Molecular Biologists to Develop customized client defined target based screens Repertoire of screens |
|
Target Classes
|